Kathleen M. Giacomini, Ph.D.
University of California, San Francisco | Pharmacogenetics of Membrane Transporters (PMT)  |
Julie A. Johnson, Pharm.D.
University of Florida, Gainesville | Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) |
John Kelsoe, M.D.
University of California, San Diego | Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD) |
Ronald M. Krauss, M.D.
Children's Hospital Oakland Research Institute, California | Pharmacogenomics and Risk of Cardiovascular Disease (PARC) |
| Caryn Lerman, Ph.D., University of Pennsylvania, Philadelphia and Rachel F. Tyndale, Ph.D., University of Toronto | Pharmacogenetics of Nicotine Addiction Treatment (PNAT) |
Mark J. Ratain, M.D., Nancy J. Cox, Ph.D. and M. Eileen Dolan, Ph.D.
University of Chicago | Pharmacogenetics of Anticancer Agents (PAAR) |
Mary V. Relling, Pharm.D.
St. Jude Children's Research Hospital, Memphis, Tennessee | Pharmacogenomics of Anticancer Agents Research in Children (PAAR4Kids) |
Dan M. Roden, M.D.
Vanderbilt University Medical Center, Nashville, Tennessee | Pharmacogenomics of Arrhythmia Therapy (PAT) |
Wolfgang Sadee, Dr.rer.nat., M. Pharmacy
The Ohio State University, Columbus | Expression Genetics in Drug Therapy (XGEN) |
Alan R. Shuldiner, M.D.
University of Maryland School of Medicine, Baltimore | The Amish Pharmacogenomics of Anti-Platelet Intervention Study (PAPI) |
Kenneth E. Thummel, Ph.D. and Wylie Burke, M.D., Ph.D.
University of Washington, Seattle | Pharmacogenetics in Rural and Underserved Populations (NWAP) |
Richard Weinshilboum, M.D.
Mayo Clinic, Rochester, Minn. | Pharmacogenetics of Phase II Drug Metabolizing Enzymes (PPII) |
Scott T. Weiss, M.D., M.S. and Kelan G. Tantisira, M.D., M.P.H.
Brigham and Women's Hospital and Harvard Medical School, Boston | Pharmacogenetics of Asthma Treatment (PHAT) |
Robert Plenge, M.D., Ph.D.
Brigham and Women's Hospital, Boston | Pharmacogenomics of Rheumatoid Arthritis Therapy (PhRAT) |